G42 Healthcare expands clinical genetics in the UAE

G42 Healthcare expands clinical genetics in the UAE

G42 Healthcare, Abu Dhabi-based leading health-tech company transforming the UAE’s healthcare landscape with AI and advanced medical technologies, has scaled up efforts to offer its clinical genetic testing solutions in the UAE. The company has launched over 250 comprehensive clinical genetic testing panels that use state-of-the-art sequencing technologies, with the shortest turnaround time.

In his comments, Dr Fahed Al Marzooqi, Chief Operating Officer of G42 Healthcare, said: “As part of our efforts to support the health of future generations and provide better healthcare every day, Biogenix Labs is expanding its clinical genetics offering in the region and reinforcing its reputation as the regional testing provider of choice.”

“We will soon be expanding this offering to the Kingdom of Saudi Arabia and the wider GCC region as well,” Dr Al Marzooqi concluded.

These diagnostic tests or biomarkers help assess high-risk patients and aid in the early detection of diseases, their prognosis, therapy selection, response to treatment, and chances of recurrence. With the enhanced offering of more than 5,000 whole-genome sequencing per week and over 50,000 whole-exome sequencing per week, it unlocks the possibilities for preventive and precision therapies that will transform the healthcare landscape in the UAE, enabling it to transition from sick care